Drug Profile
ADV 7809
Alternative Names: ADV-7809Latest Information Update: 17 Oct 2018
Price :
$50
*
At a glance
- Originator Advicenne
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Nephritis
Most Recent Events
- 17 Oct 2018 Discontinued - Phase-II/III for Nephritis (In adolescents, In children, In infants) in France (unspecified route)
- 05 Oct 2015 Phase-II/III clinical trials in Nephritis (In infants, In children, In adolescents) in France (unspecified route) (before October 2015)